This disclosure relates to crystalline forms of 3-acyl-buprenorphine derivatives and sustained release injectable pharmaceutical compositions for treatment of opioid dependence, pain or depression, including an aqueous suspension of crystalline 3-acyl-buprenoprhine, or a pharmaceutically acceptable salt thereof, wherein the composition does not include an organic solvent, a polylactide polymer, a polyglycolide polymer, or a copolymer of polylactide and polyglycolide. This disclosure also includes 3-acyl-buprenoprhine or a pharmaceutically acceptable salt thereof prepared in a controlled release matrix, including poly(lactide-co-glycolide), sucrose acetoisobutyrate, lecithin, diolein and a combination of two or more thereof.本揭示內容係有關用於治療鴉片類依賴症、疼痛或憂鬱症之3-醯基-丁基原啡因衍生物之結晶型和緩釋注射劑型之醫藥組成物，包含3-醯基-丁基原啡因晶型之水性懸浮液或其醫學上可接受之鹽，其中該組成物不包括有機溶劑、聚乳酸聚合物、聚乙醇酸聚合物、或聚乳酸和聚乙醇酸之共聚物。本揭示內容還包括在含有聚(乳酸-共-乙醇酸)(poly(lactide-co-glycolide))、蔗糖乙酸異丁酸酯(sucrose acetoisobutyrate)、卵磷脂(lecithin)、二油酯及其兩種或更多種之組合的控釋基質中製備3-醯基-丁基原啡因或其醫藥上可接受之鹽。
